Loading…

Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis

Background: The introduction of several new therapeutic agents for the treatment of type 2 diabetes mellitus has led to significant challenges for providers in deciding which agent to select during the disease course. Objective: To provide a relative comparison of the efficacy and safety of adding t...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2008-11, Vol.42 (11), p.1541-1551
Main Authors: Pinelli, Nicole R, Cha, Raymond, Brown, Morton B, Jaber, Linda A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c376t-cf3510726da03f2ca1cdf0a48ee7b9ea941af78bea286e28662817192a78e3e13
cites cdi_FETCH-LOGICAL-c376t-cf3510726da03f2ca1cdf0a48ee7b9ea941af78bea286e28662817192a78e3e13
container_end_page 1551
container_issue 11
container_start_page 1541
container_title The Annals of pharmacotherapy
container_volume 42
creator Pinelli, Nicole R
Cha, Raymond
Brown, Morton B
Jaber, Linda A
description Background: The introduction of several new therapeutic agents for the treatment of type 2 diabetes mellitus has led to significant challenges for providers in deciding which agent to select during the disease course. Objective: To provide a relative comparison of the efficacy and safety of adding thiazolidinediones (TZDs) or exenatide to oral agents for the management of type 2 diabetes mellitus by performing meta-analyses of relevant published studies. Methods: We systematically searched PubMed, MEDLINE, CINHAL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE (inception to March 2008 for all databases), and abstracts presented at the 2006 and 2007 American Diabetes Association conferences to identify all relevant publications. Studies were included in the analysis if they (1) were published in English, (2) were prospective, randomized, and controlled with placebo or comparator, (3) were at least 24 weeks' duration, (4) included nonpregnant adults with type 2 diabetes, (5) were full-text, peer-reviewed articles examining the efficacy of either TZDs (rosiglitazone or pioglitazone) or exenatide in combination with other oral drugs, and (6) included hemoglobin A1C (AIC) outcomes in a manner that allowed data analysis. We evaluated mean change in A1C levels, proportion of subjects reaching A1C goals of less than 7%, mean change in fasting plasma glucose (FPG) and body weight, and the occurrence of nonsevere hypoglycemia and gastrointestinal adverse events. Results: A total of 5212 TZD and 3562 exenatide publications were identified. After critical evaluation, 22 publications met all of the inclusion criteria for the meta-analysis. A1C was reduced from baseline for TZDs (weighted mean difference –0.80%; 95% CI –1.10 to –0.50) and exenaiide (weighted mean difference –0.60%; 95% CI –1.04 to –0.16), Compared with controls, TZD- and exenatide-based therapies had odds ratios greater than 1 for reaching A1C targets of less than 7% (TZD OR 2.27; 95% CI 1.22 to 4.24 and exenatide OR 2.90; 95% CI 1.28 to 6.55). FPG concentrations were reduced significantly from baseline in the TZD-based regimens (weighted mean difference –29.58 mg/dL; 95% CI –39.27 to –19.89), but did not achieve significance in the exenatide trials (weighted mean difference –8.77 mg/dL; 95% CI –28.85 to 11.31). Body weight was reduced with exenatide (weighted mean difference –2.74 kg; 95% CI –4.85 to –0.64) and increased in subgroup analyses for TZDs (we
doi_str_mv 10.1345/aph.1L198
format article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1345_aph_1L198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1L198</sage_id><sourcerecordid>10.1345_aph.1L198</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-cf3510726da03f2ca1cdf0a48ee7b9ea941af78bea286e28662817192a78e3e13</originalsourceid><addsrcrecordid>eNpt0UtLAzEQB_Agiu-DX0ByUfGwNZN9JOtt8Q2VXupRwnR3to1sd0uyUuunN9qiFw9hQvgxw_zD2AmIAcRJeoWL2QCGkOsttg9pIqNMKrEd7iITkZBa7LED79-EEDnIfJftgc5Tlclsn70WVWV727W8q_l4ZvGza2xlW6rCG_HO8bsParG3FfG-4yOHDS-m1Pae25aPVwvikt9anFBP_poX_Jl6jIoWm5W3_ojt1Nh4Ot7UQ_Zyfze-eYyGo4enm2IYlbHK-qis4xSEklmFIq5liVBWtcBEE6lJTpgngLXSE0KpMwonkxoU5BKVppggPmSX676l67x3VJuFs3N0KwPCfEdkQkTmJ6JgT9d28T6ZU_UnN5kEcLYB6Etsaodtaf2vk0LHIlUquPO18zgl89a9u7C1_3fixRrO7HS2tI6Mn2PThPlglstlIg2ACf8G8RezRIfL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024: Reading List</source><creator>Pinelli, Nicole R ; Cha, Raymond ; Brown, Morton B ; Jaber, Linda A</creator><creatorcontrib>Pinelli, Nicole R ; Cha, Raymond ; Brown, Morton B ; Jaber, Linda A</creatorcontrib><description>Background: The introduction of several new therapeutic agents for the treatment of type 2 diabetes mellitus has led to significant challenges for providers in deciding which agent to select during the disease course. Objective: To provide a relative comparison of the efficacy and safety of adding thiazolidinediones (TZDs) or exenatide to oral agents for the management of type 2 diabetes mellitus by performing meta-analyses of relevant published studies. Methods: We systematically searched PubMed, MEDLINE, CINHAL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE (inception to March 2008 for all databases), and abstracts presented at the 2006 and 2007 American Diabetes Association conferences to identify all relevant publications. Studies were included in the analysis if they (1) were published in English, (2) were prospective, randomized, and controlled with placebo or comparator, (3) were at least 24 weeks' duration, (4) included nonpregnant adults with type 2 diabetes, (5) were full-text, peer-reviewed articles examining the efficacy of either TZDs (rosiglitazone or pioglitazone) or exenatide in combination with other oral drugs, and (6) included hemoglobin A1C (AIC) outcomes in a manner that allowed data analysis. We evaluated mean change in A1C levels, proportion of subjects reaching A1C goals of less than 7%, mean change in fasting plasma glucose (FPG) and body weight, and the occurrence of nonsevere hypoglycemia and gastrointestinal adverse events. Results: A total of 5212 TZD and 3562 exenatide publications were identified. After critical evaluation, 22 publications met all of the inclusion criteria for the meta-analysis. A1C was reduced from baseline for TZDs (weighted mean difference –0.80%; 95% CI –1.10 to –0.50) and exenaiide (weighted mean difference –0.60%; 95% CI –1.04 to –0.16), Compared with controls, TZD- and exenatide-based therapies had odds ratios greater than 1 for reaching A1C targets of less than 7% (TZD OR 2.27; 95% CI 1.22 to 4.24 and exenatide OR 2.90; 95% CI 1.28 to 6.55). FPG concentrations were reduced significantly from baseline in the TZD-based regimens (weighted mean difference –29.58 mg/dL; 95% CI –39.27 to –19.89), but did not achieve significance in the exenatide trials (weighted mean difference –8.77 mg/dL; 95% CI –28.85 to 11.31). Body weight was reduced with exenatide (weighted mean difference –2.74 kg; 95% CI –4.85 to –0.64) and increased in subgroup analyses for TZDs (weighted mean difference 2.19 kg; 95% CI 1.24 to 3.14). There was no significant association between TZD or exenatide therapy and the risk of nonsevere hypoglycemia. The odds ratios for nausea, vomiting, and diarrhea with exenatide relative to controls were 9.02 (95% CI 3.66 to 22.23), 4.56 (95% CI 3.13 to 6.65), and 2.96 (95% CI 2.05 to 4.26), respectively. Conclusions: TZDs and exenatide have modest but beneficial effects on glycemic control and are relatively safe in regard to the adverse events studied. TZDs produce greater improvement in glycemic control, while exenatide Is associated with reduction in body weight.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1L198</identifier><identifier>PMID: 18957626</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Biological and medical sciences ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Drug Therapy, Combination ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Humans ; Hypoglycemic Agents - administration &amp; dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Medical sciences ; Peptides - administration &amp; dosage ; Peptides - adverse effects ; Peptides - therapeutic use ; Pharmacology. Drug treatments ; Thiazolidinediones - administration &amp; dosage ; Thiazolidinediones - adverse effects ; Thiazolidinediones - therapeutic use ; Venoms - administration &amp; dosage ; Venoms - adverse effects ; Venoms - therapeutic use</subject><ispartof>The Annals of pharmacotherapy, 2008-11, Vol.42 (11), p.1541-1551</ispartof><rights>2008 SAGE Publications</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-cf3510726da03f2ca1cdf0a48ee7b9ea941af78bea286e28662817192a78e3e13</citedby><cites>FETCH-LOGICAL-c376t-cf3510726da03f2ca1cdf0a48ee7b9ea941af78bea286e28662817192a78e3e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20830577$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18957626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pinelli, Nicole R</creatorcontrib><creatorcontrib>Cha, Raymond</creatorcontrib><creatorcontrib>Brown, Morton B</creatorcontrib><creatorcontrib>Jaber, Linda A</creatorcontrib><title>Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>Background: The introduction of several new therapeutic agents for the treatment of type 2 diabetes mellitus has led to significant challenges for providers in deciding which agent to select during the disease course. Objective: To provide a relative comparison of the efficacy and safety of adding thiazolidinediones (TZDs) or exenatide to oral agents for the management of type 2 diabetes mellitus by performing meta-analyses of relevant published studies. Methods: We systematically searched PubMed, MEDLINE, CINHAL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE (inception to March 2008 for all databases), and abstracts presented at the 2006 and 2007 American Diabetes Association conferences to identify all relevant publications. Studies were included in the analysis if they (1) were published in English, (2) were prospective, randomized, and controlled with placebo or comparator, (3) were at least 24 weeks' duration, (4) included nonpregnant adults with type 2 diabetes, (5) were full-text, peer-reviewed articles examining the efficacy of either TZDs (rosiglitazone or pioglitazone) or exenatide in combination with other oral drugs, and (6) included hemoglobin A1C (AIC) outcomes in a manner that allowed data analysis. We evaluated mean change in A1C levels, proportion of subjects reaching A1C goals of less than 7%, mean change in fasting plasma glucose (FPG) and body weight, and the occurrence of nonsevere hypoglycemia and gastrointestinal adverse events. Results: A total of 5212 TZD and 3562 exenatide publications were identified. After critical evaluation, 22 publications met all of the inclusion criteria for the meta-analysis. A1C was reduced from baseline for TZDs (weighted mean difference –0.80%; 95% CI –1.10 to –0.50) and exenaiide (weighted mean difference –0.60%; 95% CI –1.04 to –0.16), Compared with controls, TZD- and exenatide-based therapies had odds ratios greater than 1 for reaching A1C targets of less than 7% (TZD OR 2.27; 95% CI 1.22 to 4.24 and exenatide OR 2.90; 95% CI 1.28 to 6.55). FPG concentrations were reduced significantly from baseline in the TZD-based regimens (weighted mean difference –29.58 mg/dL; 95% CI –39.27 to –19.89), but did not achieve significance in the exenatide trials (weighted mean difference –8.77 mg/dL; 95% CI –28.85 to 11.31). Body weight was reduced with exenatide (weighted mean difference –2.74 kg; 95% CI –4.85 to –0.64) and increased in subgroup analyses for TZDs (weighted mean difference 2.19 kg; 95% CI 1.24 to 3.14). There was no significant association between TZD or exenatide therapy and the risk of nonsevere hypoglycemia. The odds ratios for nausea, vomiting, and diarrhea with exenatide relative to controls were 9.02 (95% CI 3.66 to 22.23), 4.56 (95% CI 3.13 to 6.65), and 2.96 (95% CI 2.05 to 4.26), respectively. Conclusions: TZDs and exenatide have modest but beneficial effects on glycemic control and are relatively safe in regard to the adverse events studied. TZDs produce greater improvement in glycemic control, while exenatide Is associated with reduction in body weight.</description><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Drug Therapy, Combination</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration &amp; dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Medical sciences</subject><subject>Peptides - administration &amp; dosage</subject><subject>Peptides - adverse effects</subject><subject>Peptides - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Thiazolidinediones - administration &amp; dosage</subject><subject>Thiazolidinediones - adverse effects</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>Venoms - administration &amp; dosage</subject><subject>Venoms - adverse effects</subject><subject>Venoms - therapeutic use</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNpt0UtLAzEQB_Agiu-DX0ByUfGwNZN9JOtt8Q2VXupRwnR3to1sd0uyUuunN9qiFw9hQvgxw_zD2AmIAcRJeoWL2QCGkOsttg9pIqNMKrEd7iITkZBa7LED79-EEDnIfJftgc5Tlclsn70WVWV727W8q_l4ZvGza2xlW6rCG_HO8bsParG3FfG-4yOHDS-m1Pae25aPVwvikt9anFBP_poX_Jl6jIoWm5W3_ojt1Nh4Ot7UQ_Zyfze-eYyGo4enm2IYlbHK-qis4xSEklmFIq5liVBWtcBEE6lJTpgngLXSE0KpMwonkxoU5BKVppggPmSX676l67x3VJuFs3N0KwPCfEdkQkTmJ6JgT9d28T6ZU_UnN5kEcLYB6Etsaodtaf2vk0LHIlUquPO18zgl89a9u7C1_3fixRrO7HS2tI6Mn2PThPlglstlIg2ACf8G8RezRIfL</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Pinelli, Nicole R</creator><creator>Cha, Raymond</creator><creator>Brown, Morton B</creator><creator>Jaber, Linda A</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20081101</creationdate><title>Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis</title><author>Pinelli, Nicole R ; Cha, Raymond ; Brown, Morton B ; Jaber, Linda A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-cf3510726da03f2ca1cdf0a48ee7b9ea941af78bea286e28662817192a78e3e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Drug Therapy, Combination</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration &amp; dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Medical sciences</topic><topic>Peptides - administration &amp; dosage</topic><topic>Peptides - adverse effects</topic><topic>Peptides - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Thiazolidinediones - administration &amp; dosage</topic><topic>Thiazolidinediones - adverse effects</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>Venoms - administration &amp; dosage</topic><topic>Venoms - adverse effects</topic><topic>Venoms - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pinelli, Nicole R</creatorcontrib><creatorcontrib>Cha, Raymond</creatorcontrib><creatorcontrib>Brown, Morton B</creatorcontrib><creatorcontrib>Jaber, Linda A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pinelli, Nicole R</au><au>Cha, Raymond</au><au>Brown, Morton B</au><au>Jaber, Linda A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>42</volume><issue>11</issue><spage>1541</spage><epage>1551</epage><pages>1541-1551</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>Background: The introduction of several new therapeutic agents for the treatment of type 2 diabetes mellitus has led to significant challenges for providers in deciding which agent to select during the disease course. Objective: To provide a relative comparison of the efficacy and safety of adding thiazolidinediones (TZDs) or exenatide to oral agents for the management of type 2 diabetes mellitus by performing meta-analyses of relevant published studies. Methods: We systematically searched PubMed, MEDLINE, CINHAL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, EMBASE (inception to March 2008 for all databases), and abstracts presented at the 2006 and 2007 American Diabetes Association conferences to identify all relevant publications. Studies were included in the analysis if they (1) were published in English, (2) were prospective, randomized, and controlled with placebo or comparator, (3) were at least 24 weeks' duration, (4) included nonpregnant adults with type 2 diabetes, (5) were full-text, peer-reviewed articles examining the efficacy of either TZDs (rosiglitazone or pioglitazone) or exenatide in combination with other oral drugs, and (6) included hemoglobin A1C (AIC) outcomes in a manner that allowed data analysis. We evaluated mean change in A1C levels, proportion of subjects reaching A1C goals of less than 7%, mean change in fasting plasma glucose (FPG) and body weight, and the occurrence of nonsevere hypoglycemia and gastrointestinal adverse events. Results: A total of 5212 TZD and 3562 exenatide publications were identified. After critical evaluation, 22 publications met all of the inclusion criteria for the meta-analysis. A1C was reduced from baseline for TZDs (weighted mean difference –0.80%; 95% CI –1.10 to –0.50) and exenaiide (weighted mean difference –0.60%; 95% CI –1.04 to –0.16), Compared with controls, TZD- and exenatide-based therapies had odds ratios greater than 1 for reaching A1C targets of less than 7% (TZD OR 2.27; 95% CI 1.22 to 4.24 and exenatide OR 2.90; 95% CI 1.28 to 6.55). FPG concentrations were reduced significantly from baseline in the TZD-based regimens (weighted mean difference –29.58 mg/dL; 95% CI –39.27 to –19.89), but did not achieve significance in the exenatide trials (weighted mean difference –8.77 mg/dL; 95% CI –28.85 to 11.31). Body weight was reduced with exenatide (weighted mean difference –2.74 kg; 95% CI –4.85 to –0.64) and increased in subgroup analyses for TZDs (weighted mean difference 2.19 kg; 95% CI 1.24 to 3.14). There was no significant association between TZD or exenatide therapy and the risk of nonsevere hypoglycemia. The odds ratios for nausea, vomiting, and diarrhea with exenatide relative to controls were 9.02 (95% CI 3.66 to 22.23), 4.56 (95% CI 3.13 to 6.65), and 2.96 (95% CI 2.05 to 4.26), respectively. Conclusions: TZDs and exenatide have modest but beneficial effects on glycemic control and are relatively safe in regard to the adverse events studied. TZDs produce greater improvement in glycemic control, while exenatide Is associated with reduction in body weight.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>18957626</pmid><doi>10.1345/aph.1L198</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1060-0280
ispartof The Annals of pharmacotherapy, 2008-11, Vol.42 (11), p.1541-1551
issn 1060-0280
1542-6270
language eng
recordid cdi_crossref_primary_10_1345_aph_1L198
source SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024: Reading List
subjects Biological and medical sciences
Diabetes Mellitus, Type 2 - drug therapy
Diabetes. Impaired glucose tolerance
Drug Therapy, Combination
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Medical sciences
Peptides - administration & dosage
Peptides - adverse effects
Peptides - therapeutic use
Pharmacology. Drug treatments
Thiazolidinediones - administration & dosage
Thiazolidinediones - adverse effects
Thiazolidinediones - therapeutic use
Venoms - administration & dosage
Venoms - adverse effects
Venoms - therapeutic use
title Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A35%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addition%20of%20Thiazolidinedione%20or%20Exenatide%20to%20Oral%20Agents%20in%20Type%202%20Diabetes:%20A%20Meta-Analysis&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Pinelli,%20Nicole%20R&rft.date=2008-11-01&rft.volume=42&rft.issue=11&rft.spage=1541&rft.epage=1551&rft.pages=1541-1551&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1L198&rft_dat=%3Csage_cross%3E10.1345_aph.1L198%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c376t-cf3510726da03f2ca1cdf0a48ee7b9ea941af78bea286e28662817192a78e3e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/18957626&rft_sage_id=10.1345_aph.1L198&rfr_iscdi=true